CollPlant Biotechnologies Ltd (CLGN) stock
CLGNNasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31Also trades as OPHI
$3.96+0.06 (+1.54%)
Close on Nov 11, 2026Market cap –P/E –Yield –
CollPlant Biotechnologies r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $8.19M, down 22.1% from the year before. The highest annual figure on record is $10.52M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.19M | -22.1% |
| FY2024 | Dec 31, 2024 | $10.52M | +0.3% |
| FY2023 | Dec 31, 2023 | $10.48M | +2.2% |
| FY2022 | Dec 31, 2022 | $10.26M | +34.4% |
| FY2021 | Dec 31, 2021 | $7.63M | +87.7% |
| FY2020 | Dec 31, 2020 | $4.07M | -7.9% |
| FY2019 | Dec 31, 2019 | $4.41M | +13.9% |
| FY2018 | Dec 31, 2018 | $3.88M | +563.9% |
| FY2017 | Dec 31, 2017 | $584.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025 | Jun 30, 2025 | $2.01M | +5.9% |
| Q2 FY2024 | Jun 30, 2024 | $2.70M | +169.2% |
| Q2 FY2023 | Jun 30, 2023 | $2.57M | +137.5% |
| Q2 FY2022 | Jun 30, 2022 | $2.60M | +305.5% |
| Q2 FY2021 | Jun 30, 2021 | $1.90M | – |
| Q2 FY2020 | Jun 30, 2020 | $1.00M | – |
| Q2 FY2019 | Jun 30, 2019 | $1.08M | – |
| Q2 FY2018 | Jun 30, 2018 | $641.00K | – |
See a number that looks wrong?